PMID- 34868954
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - The Potential Prognostic Role of Oligosaccharide-Binding Fold-Containing Protein 
      2A (OBFC2A) in Triple-Negative Breast Cancer.
PG  - 751430
LID - 10.3389/fonc.2021.751430 [doi]
LID - 751430
AB  - BACKGROUND: Patients with triple-negative breast cancer (TNBC) have poor overall 
      survival. The present study aimed to investigate the potential prognostics of 
      TNBC by analyzing breast cancer proteomic and transcriptomic datasets. METHODS: 
      Candidate proteins selected from CPTAC (the National Cancer Institute's Clinical 
      Proteomic Tumor Analysis Consortium) were validated using datasets from METABRIC 
      (Molecular Taxonomy of Breast Cancer International Consortium). Kaplan-Meier 
      analysis and ROC (receiver operating characteristic) curve analysis were 
      performed to explore the prognosis of candidate genes. GO (Gene Ontology) and 
      KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis were performed 
      on the suspected candidate genes. Single-cell RNA-seq (scRNA-seq) data from 
      GSE118389 were used to analyze the cell clusters in which OBFC2A 
      (Oligosaccharide-Binding Fold-Containing Protein 2A) was mainly distributed. 
      TIMER (Tumor Immune Estimation Resource) was used to verify the correlation 
      between OBFC2A expression and immune infiltration. Clone formation assays and 
      wound healing assays were used to detect the role of OBFC2A expression on the 
      proliferation, invasion, and migration of breast cancer cells. Flow cytometry was 
      used to analyze the effects of silencing OBFC2A on breast cancer cell cycle and 
      apoptosis. RESULTS: Six candidate proteins were found to be differentially 
      expressed in non-TNBC and TNBC groups from CPTAC. However, only OBFC2A was 
      identified as an independently poor prognostic gene marker in METABRIC (HR=3.658, 
      1.881-7.114). And OBFC2A was associated with immune functions in breast cancer. 
      Biological functional experiments showed that OBFC2A might promote the 
      proliferation and migration of breast cancer cells. The inhibition of OBFC2A 
      expression blocked the cell cycle in G1 phase and inhibited the transformation 
      from G1 phase to S phase. Finally, downregulation of OBFC2A also increased the 
      total apoptosis rate of cells. CONCLUSION: On this basis, OBFC2A may be a 
      potential prognostic biomarker for TNBC.
CI  - Copyright (c) 2021 Wu, Tang, Zhu, Li, Zhang and Li.
FAU - Wu, Qianxue
AU  - Wu Q
AD  - Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing Medical University, Chongqing, China.
FAU - Tang, Xin
AU  - Tang X
AD  - Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China.
FAU - Zhu, Wenming
AU  - Zhu W
AD  - Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing Medical University, Chongqing, China.
FAU - Li, Qing
AU  - Li Q
AD  - Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing Medical University, Chongqing, China.
FAU - Zhang, Xiang
AU  - Zhang X
AD  - Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing Medical University, Chongqing, China.
FAU - Li, Hongyuan
AU  - Li H
AD  - Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing Medical University, Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20211115
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8634334
OTO - NOTNLM
OT  - OBFC2A
OT  - molecular biology
OT  - overall survival
OT  - prognosis
OT  - triple-negative breast cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/07 06:00
MHDA- 2021/12/07 06:01
PMCR- 2021/01/01
CRDT- 2021/12/06 09:18
PHST- 2021/08/01 00:00 [received]
PHST- 2021/10/28 00:00 [accepted]
PHST- 2021/12/06 09:18 [entrez]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2021/12/07 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.751430 [doi]
PST - epublish
SO  - Front Oncol. 2021 Nov 15;11:751430. doi: 10.3389/fonc.2021.751430. eCollection 
      2021.